Stay updated with breaking news from Tomorrow Scale. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
.jpg)
Biotech Antiverse has successfully identified functional antibody clusters targeting two G-protein-coupled receptors (GPCRs), both displaying versatile binding profiles and nanomolar affinity. Click to read more...
$3 million USD (c. £2.5 million GBP) investment will enable further development of assets Successful identification of 8 antibodies with therapeutic potential for human GPCRs achieved
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
Antiverse Ltd (Antiverse), a biotechnology company developing a computational antibody drug discovery platform, today announced the successful identification of functional antibody clusters targeting two G-protein-coupled receptors (GPCRs), both displaying versatile binding profiles and nanomolar affinity.